18 and older, any sex, with Thymoma or Advanced Thymic Epithelial Tumor. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Overall Response RatePrimary· 24 months
To determine the overall response rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR+ PR.
Group
Value
95% CI
Selinexor
0
Overall Response RateSecondary· 24 months
To determine the overall response rate to according to modified ITMIG response criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT and MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
To determine overall survival of patients with TET treated with selinexor
Group
Value
95% CI
Selinexor
57.1
Adverse EventsSecondary· 24 months
The number of adverse events as determined by Common Terminology Criteria for Adverse Events (CTCAEs) version 4.03
Group
Value
95% CI
Selinexor
93
Adverse events — posted to ClinicalTrials.gov
Time frame: From the time of consent to 30 days following the last dose of study treatment (max 24 months)..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of selinexor in patients with advanced thymic epithelial tumor progressing after primary chemotherapy. This is a multicenter, open label phase II trial that uses a Simons two stage design. The study population is adults with histologically confirmed, advanced, inoperable TETs who are progressing after treatment with at least one platinum containing chemotherapy regimen.
This study is comprised of 2 similar phase II trials, one running in US (25 patients) and one running in EU (25 patients):
There are two study arms:
Arm A: Thymoma
* Stage 1: 15 patients
* Stage 2: 10 patients
Arm B: Thymic carcinoma
* Stage 1: 15 patients
* Stage 2: 10 patients
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05682742 — Clinical Investigation of the da Vinci Surgical System
· NA
· active not recruiting
Other Georgetown University trials
Trials by the same sponsor.
NCT07228000 — Bundled Cancer Screening and Genetic Services Navigation
· NA
· not yet recruiting
NCT07128927 — Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors
· NA
· recruiting
NCT06046287 — Daratumumab for Polyneuropathy Associated With MGUS
· Phase 2
· withdrawn
NCT06980103 — Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyro
· NA
· recruiting
NCT07105358 — Visual Plasticity Following Brain Lesions
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Georgetown University
Last refreshed: 16 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03193437.